» Articles » PMID: 37471377

Optimization of Infectious Bronchitis Virus-like Particle Expression in Nicotiana Benthamiana As Potential Poultry Vaccines

Overview
Journal PLoS One
Date 2023 Jul 20
PMID 37471377
Authors
Affiliations
Soon will be listed here.
Abstract

Infectious bronchitis (IB) is a highly contagious, acute respiratory disease in chickens, with a severe economic impact on poultry production globally. The rapid emergence of regional variants of this Gammacoronavirus warrants new vaccine approaches that are more humane and rapid to produce than the current embryonated chicken egg-based method used for IB variant vaccine propagation (chemically-inactivated whole viruses). The production of virus-like particles (VLPs) expressing the Spike (S) glycoprotein, the major antigen which induces neutralizing antibodies, has not been achieved in planta up until now. In this study, using the Agrobacterium-mediated Nicotiana benthamiana (tobacco plant) transient expression system, the highest levels of VLPs displaying a modified S protein of a QX-like IB variant were obtained when the native transmembrane (TM) domain and cytoplasmic tail were substituted with that of the Newcastle disease virus (NDV) fusion glycoprotein, co-infiltrated with the NDV Matrix protein. In comparison, the native IB modified S co-infiltrated with IB virus membrane, envelope and nucleocapsid proteins, or substituted with the TM and CT of an H6-subtype influenza A virus hemagglutinin glycoprotein yielded lower VLP expression levels. Strong immunogenicity was confirmed in specific pathogen free chickens immunized intramuscularly with VLPs adjuvanted with Emulsigen®-P, where birds that received doses of 5 μg or 20 μg (S protein content) seroconverted after two weeks with mean hemaggluttination inhibition titres of 9.1 and 10 log2, respectively. Plant-produced IB VLP variant vaccines are safer, more rapid and cost effective to produce than VLPs produced in insect cell expression systems or the traditional egg-produced inactivated whole virus oil emulsion vaccines currently in use, with great potential for improved IB disease control in future.

Citing Articles

Protein Expression Platforms and the Challenges of Viral Antigen Production.

Sookhoo J, Schiffman Z, Ambagala A, Kobasa D, Pardee K, Babiuk S Vaccines (Basel). 2025; 12(12.

PMID: 39772006 PMC: 11680109. DOI: 10.3390/vaccines12121344.


Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development.

Mardanova E, Vasyagin E, Ravin N Plants (Basel). 2025; 13(24.

PMID: 39771262 PMC: 11678810. DOI: 10.3390/plants13243564.


Virus-like particles in poultry disease: an approach to effective and safe vaccination.

Raji A, Dastjerdi P, Omar A Front Vet Sci. 2024; 11:1405605.

PMID: 39315089 PMC: 11417104. DOI: 10.3389/fvets.2024.1405605.


Tailored Viral-like Particles as Drivers of Medical Breakthroughs.

Travassos R, Martins S, Fernandes A, Correia J, Melo R Int J Mol Sci. 2024; 25(12).

PMID: 38928403 PMC: 11204272. DOI: 10.3390/ijms25126699.

References
1.
Rybicki E . Plant-produced vaccines: promise and reality. Drug Discov Today. 2008; 14(1-2):16-24. DOI: 10.1016/j.drudis.2008.10.002. View

2.
Jutras P, DAoust M, Couture M, Vezina L, Goulet M, Michaud D . Modulating secretory pathway pH by proton channel co-expression can increase recombinant protein stability in plants. Biotechnol J. 2015; 10(9):1478-86. DOI: 10.1002/biot.201500056. View

3.
Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L . Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J. 2008; 6(4):392-402. DOI: 10.1111/j.1467-7652.2008.00330.x. View

4.
Ujike M, Taguchi F . Incorporation of spike and membrane glycoproteins into coronavirus virions. Viruses. 2015; 7(4):1700-25. PMC: 4411675. DOI: 10.3390/v7041700. View

5.
Liu G, Lv L, Yin L, Li X, Luo D, Liu K . Assembly and immunogenicity of coronavirus-like particles carrying infectious bronchitis virus M and S proteins. Vaccine. 2013; 31(47):5524-30. PMC: 7115625. DOI: 10.1016/j.vaccine.2013.09.024. View